Biomarker Research

Biomarker Research accepted for inclusion in SCIE

We are delighted to announce that Biomarker Research has been accepted for inclusion in Science Citation Index Expanded (SCIE), a key database of Web of Science, published by Clarivate Analytics. Starting 2020, Biomarker Research will be published in the annual Journal Citation Reports, at which point it will receive the associated journal metrics, such as Immediacy Index, Eigenfactor Score, and Journal Impact Factor.

We would like to thank everyone for supporting Biomarker Research and contributing to this success.

Content type: Review
| 11 April 2019

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

Authors: Amandeep Aujla, Ravijot Aujla and Delong Liu
Content type: Review
| 4 April 2019

Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm

Authors: Kan Yin, Shihua Wang and Robert Chunhua Zhao
Content type: Research
| 3 April 2019

The association between early neurological deterioration and whole blood purine concentration during acute stroke

Authors: Alexander J. Martin, Nicholas Dale, Christopher H. E. Imray, Christine Roffe, Craig J. Smith, Faming Tian and Christopher I. Price
Content type: Review
| 18 March 2019

Novel insights into MSC-EVs therapy for immune diseases

Authors: Peilong Lai, Jianyu Weng, Liyan Guo, Xiaomei Chen and Xin Du
Content type: Short report
| 8 March 2019

Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma

Authors: Emily M. Christman, Parthasarathy Chandrakesan, Nathaniel Weygant, John T. Maple, William M. Tierney, Kenneth J. Vega and Courtney W. Houchen

Most recent articles RSS

View all articles

Content type: Research
| 7 April 2016

The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer

Authors: Elisabeth Hofmann, Rita Seeboeck, Nico Jacobi, Peter Obrist, Samuel Huter, Christian Klein, Kamil Oender, Christoph Wiesner, Harald Hundsberger and Andreas Eger
Content type: Review
| 1 April 2013

Metabolomic analyses for atherosclerosis, diabetes, and obesity

Authors: Fuyong Du, Anthony Virtue, Hong Wang and Xiao-Feng Yang
Content type: Review
| 7 January 2014

Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases

Authors: Jiyeon Yang, Lixiao Zhang, Caijia Yu, Xiao-Feng Yang and Hong Wang
Content type: Review
| 10 February 2014

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies

Authors: Ugo Testa, Elvira Pelosi and Arthur Frankel
Content type: Review
| 5 February 2013

Biomarkers for hepatocellular carcinoma: progression in early diagnosis, prognosis, and personalized therapy

Authors: Kai Zhu, Zhi Dai and Jian Zhou

Most accessed articles RSS

View all articles

Editors-in-Chief

Chung-Tsen Hsueh, Loma Linda University

Delong Liu, New York Medical College

Aims and scope

Biomarker Research is an open access, peer-reviewed journal that encompasses all aspects of biomarker investigation. Biomarker Research aims to publish original discoveries, novel concepts, commentaries and reviews related to biomarker investigation from all biomedical disciplines.

The study of biomarkers has evolved rapidly in the advance of personalized medicine and individual health. The identification and validation of biomarkers in drug discovery/development and in disease diagnosis, treatment, prognosis, and prevention play an essential role in the genome era. With a quick turnaround time from submission to publication and online feedback from readers, Biomarker Research strives to provide fast dissemination of novel findings and new knowledge.

Latest Tweets

Featured review: EZH2 as a therapeutic target for multiple myeloma

This article by Dr. Tremblay-LeMay et al. reviews the evidence supporting the role of EZH2 in MM pathophysiology and drug resistance, with an emphasis on interactions between EZH2 and microRNAs, as well as the prognostic significance of EZH2 expression in MM. Furthermore, results from the pre-clinical studies of EZH2 inhibition in MM and currently available interim results from clinical trials of EZH2 inhibitors in haematological malignancies are presented.

Biomarker Research